PDE5A and Alzheimer disease: Although inhibitors of cGMP-specific PDEs, namely PDE5 and PDE9, have been shown to exert neuroprotective and memory-enhancing effects in a variety of AD animal models, their translation in clinical trials has not yet yielded consistent results [164,165].